All In Biotech

Drug Trial Radar · NCT00468728

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)

Last checked: Nov 19, 2026Latest source record: Apr 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 535 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

535

Actual

Start

Oct 4, 2006

Primary completion

Dec 11, 2009

Study completion Dec 11, 2009

Sponsor

Sponsor type
Industry
First posted
May 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).

Conditions

  • Clostridium Infections
  • Diarrhea

Interventions

  • PAR-101/OPT-80Drug

    capsules

  • VancomycinDrug

    Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure Rate at End of TherapyTime frame: Study day 10 (+/- 2 days)

Locations

116 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Gadsden, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    La Mesa, California

  • Site not named

    Modesto, California

  • Site not named

    Palm Springs, California

  • Site not named

    Rancho Mirage, California

  • Site not named

    San Jose, California

  • Site not named

    Santa Ana, California

  • Site not named

    Vallejo, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Miami, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Marietta, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Bowling Green, Kentucky

  • Site not named

    Jena, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    West Roxbury, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Keego Harbor, Michigan

  • Site not named

    Royal Oak, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Tupelo, Mississippi

  • Site not named

    Columbia, Missouri

  • Site not named

    Butte, Montana

  • Site not named

    Cedar Knolls, New Jersey

  • Site not named

    Neptune City, New Jersey

  • Site not named

    The Bronx, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Fargo, North Dakota

  • Site not named

    Akron, Ohio

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.